Cartesian Therapeutics, Inc. (RNAC)

NASDAQ: RNAC · Real-Time Price · USD

6.07

-0.53 (-8.03%)

At close: Mar 24, 2026, 4:00 PM EDT

6.05

-0.02 (-0.30%)

After-hours: Mar 24, 2026, 6:53 PM EDT

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Research and Development of Cell Therapy Product Candidates	2.80M	38.91M	26.00M	110.78M	85.08M
Research and Development of Cell Therapy Product Candidates Growth	-92.81%	49.64%	-76.53%	30.21%	-
Total	2.80M	38.91M	26.00M	110.78M	85.08M
Total Growth	-92.81%	49.64%	-76.53%	30.21%	-

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
United States	2.80M	38.91M	26.00M	110.78M	85.08M
United States Growth	-92.81%	49.64%	-76.53%	30.21%	-
Total	2.80M	38.91M	26.00M	110.78M	85.08M
Total Growth	-92.81%	49.64%	-76.53%	30.21%	-

Source: S&P Global Market Intelligence.